OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.7 weeks (median values) after submission.
Submission Deadline: September 15, 2020 (Open) Submit Now
Yvonne A. Efebera, MD
Associate Professor, Blood and Marrow Transplantation Program, Ohio State University, Columbus, Ohio, USA
Research Interests: Multiple myeloma; graft vs host disease; paraproteinemias; amyloidosis; necrobiotic xanthogranuloma; blood and marrow transplantation
About This Topic
Allogeneic hematopoietic stem cell transplant (alloHSCT) is a curative treatment for many hematologic malignancies. Unfortunately, about 30-50% of all recipients undergoing alloHSCT develop acute and chronic graft-versus-host-disease (aGVHD), which is associated with high morbidity and mortality [1, 2]. The pathophysiology of aGVHD is complex but involves the activation of host antigen presenting cells (APCs) by recipient conditioning which in turn activate transplanted donor T lymphocytes that expand and differentiate into effector cells that mediate cytotoxicity against recipient tissues through Fas-Fas ligand interactions, perforin-granzyme B, and cytokine production [2, 3, 4, 5]. When severe, aGVHD carries a poor prognosis, with only 25% long term survival for grade III and 5% for grade IV . Major contributing factors to severity of GVHD include HLA mismatch, conditioning regimen intensity, age of donor and recipient, source of stem cell (Peripheral blood, bone marrow, cord blood), and donor type (related, unrelated, haploidentical). Strategies and clinical trials are ongoing to reduce the incidence of GVHD, and to improve on the survival outcome of patients with GVHD, including the assessment of microRNAs and use of biomarkers guided management. This issue welcomes submission in any areas that focuses on GVHD mitigation and management.
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012; 12: 443-458.[CrossRef]
Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373: 1550-1561.[CrossRef]
Socie G, Blazar BR. Acute graft-versus-host disease: From the bench to the bedside. Blood. 2009; 114: 4327-4336.[CrossRef]
Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996; 87: 1232-1237.
Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987; 166: 1280-1289.
Deeg HJ. How I treat refractory acute GVHD. Blood. 2007; 109: 4119-4126.[CrossRef]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.